{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:08:17Z","timestamp":1787875697325,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>This pathology PILOT study aims to define the role and feasibility of centralized pathology review in a cohort of 75 patients from different centers in the United States and Europe using digital slide scanning. The pathologic material from 75 patients who had been diagnosed with mycosis fungoides\/S\u00e9zary syndrome and were clinically staged as IIb or above was retrieved from 11 participating centers. Each pathology reviewer was provided with the pathologic diagnosis (by the referring pathologist), and the following list of histopathologic criteria (presence or absence) from the initial report: epidermotropism, folliculotropism (FT), large cell transformation, syringotropism, and granulomas. Patients with advance stage were selected for this study as this is a population where there is significant variability in the diagnosis of pathologic prognostic and predictive biomarkers. The slides were digitally scanned with an Aperio scanner and consensus review of cases occurred when major or minor discrepancies between the referral diagnosis and central pathology review occurred. Among the 75 cases, 70 (93.3%) had a final consensus diagnosis between the 3 central review pathologists. The overall agreement between the consensus review and the referring pathologist was 60%. The overall agreement was also higher between the reviewers and consensus review, compared with the referring pathologist and consensus. 65.3% of cases had some type of discrepancy (major or minor) between the outside and consensus review. Major discrepancies were seen in 34 of 73 cases (46.6%; 73 cases indicated a yes or no response). Minor discrepancies were seen in 32 of 75 (42.7%) of cases. Most of the major discrepancies were accounted by a difference in interpretation in the presence or absence of large cell transformation or FT. Most minor discrepancies were explained by a different interpretation in the expression of CD30. We found digital slide scanning to be a beneficial, reliable, and practical for a methodical approach to perform central pathology review in the context of a large clinical prospective study.<\/jats:p>","DOI":"10.1097\/pas.0000000000001041","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T17:19:53Z","timestamp":1521134393000},"page":"726-734","source":"Crossref","is-referenced-by-count":21,"title":["The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and S\u00e9zary Syndrome"],"prefix":"10.1097","volume":"42","author":[{"given":"Alejandro A.","family":"Gru","sequence":"first","affiliation":[{"name":"Pathology and Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinah","family":"Kim","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pulitzer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital St Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cerroni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kempf","sequence":"additional","affiliation":[{"name":"Kempf und Pfaltz, Diagnostic Histopathology, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Leiden, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Pawade","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[{"name":"Division of Dermatology, City of Hope, Duarte"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Washington University in St Louis School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pincus","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tetzlaff","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"Dermatology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"DiCaudo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Hong","sequence":"additional","affiliation":[{"name":"Dermatology, Stanford University, Palo Alto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Horton","sequence":"additional","affiliation":[{"name":"Public Health Sciences, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Dermatology, Stanford University, Palo Alto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and Sezary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/cncr.28676","article-title":"Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network","volume":"120","author":"Herrera","year":"2014","journal-title":"Cancer"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/hon.2316","article-title":"Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study","volume":"35","author":"Bellei","year":"2017","journal-title":"Hematol Oncol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0560.2001.028004174.x","article-title":"Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting","volume":"28","author":"Guitart","year":"2001","journal-title":"J Cutan Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/3JK2H6Y988NUAY37","article-title":"Usefulness (or lack thereof) of immunophenotyping in atypical cutaneous T-cell infiltrates","volume":"125","author":"Florell","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"issue":"part 1","key":"R16-20230922","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/Sezary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archderm.144.6.738","article-title":"Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma","volume":"144","author":"Gerami","year":"2008","journal-title":"Arch Dermatol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijd.IJD_73_17","article-title":"New targeted treatments for cutaneous T-cell lymphomas","volume":"62","author":"Bagot","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2016.11.009","article-title":"Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review","volume":"109","author":"Berger","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"part 1","key":"R27-20230922","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/jid.2011.351","article-title":"High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides","volume":"132","author":"Kadin","year":"2012","journal-title":"J Invest Dermatol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201806000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:35:30Z","timestamp":1695422130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201806000-00004"}},"subtitle":["A Multi-institutional and International Pathology Study"],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001041","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}